entX’s Nuclear Medicine business involves developing process technology for the recovery of valuable isotopes from low level radioactive waste streams for production of precursor materials that will go into a number of critical and emerging cancer therapy treatments. The benefit for Australian and other global cancer therapy markets is breaking the reliance on existing supply chains in countries with increasing stability arising from recent geopolitical issues. Creating this sovereign supply chain will benefit availability and cost of future cancer treatment.